ArticleBriefings in bioinformatics2024
ACP-CapsPred: an explainable computational framework for identification and functional prediction of anticancer peptides based on capsule network.
Article in Briefings in bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- DeepACPred: an integrated multistage framework for anticancer peptide discovery and activity prediction.Briefings in bioinformatics · 2026Article
- CKAN-ATHP: a predictor for antihypertensive peptides based on sample augmentation and loss improvement strategies using the convolutional Kolmogorov-Arnold network.Journal of cheminformatics · 2026Article
- Multi-ACPNet: A multi-scale sequence-structure feature fusion framework for anticancer peptide identification and functional prediction.PLoS computational biology · 2026Article
- IQSPred-PLM: An Interpretable Quorum Sensing Peptides Prediction Model Based on Protein Language Model.Interdisciplinary sciences, computational life sciences · 2026Article
- IL2Pepscan: A machine learning framework for predicting IL-2 inducing peptides and their identification across global viral proteomes.Scientific reports · 2026Article
- Transfer learning on protein language models improves antimicrobial peptide classification.Scientific reports · 2025Article
- Toward high-efficiency, low-resource, and explainable neuropeptide prediction with MSKDNP.Briefings in bioinformatics · 2025Article
- AAGP integrates physicochemical and compositional features for machine learning-based prediction of anti-aging peptides.Scientific reports · 2025Article
- A hybrid framework of generative deep learning for antiviral peptide discovery.Scientific reports · 2025Article
- CAP-m7G: A capsule network-based framework for specific RNA N7-methylguanosine site identification using image encoding and reconstruction layers.Computational and structural biotechnology journal · 2025Article
- AAindexNC: Estimating the Physicochemical Properties of Non-Canonical Amino Acids, Including Those Derived from the PDB and PDBeChem Databank.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cancer is a severe illness that significantly threatens human life and health. Anticancer peptides (ACPs) represent a promising therapeutic strategy for combating cancer. In silico methods enable rapid and accurate identification of ACPs without extensive human and material resources. This study proposes a two-stage computational framework called ACP-CapsPred, which can accurately identify ACPs and characterize their functional activities across different cancer types. ACP-CapsPred integrates a protein language model with evolutionary information and physicochemical properties of peptides, constructing a comprehensive profile of peptides. ACP-CapsPred employs a next-generation neural network, specifically capsule networks, to construct predictive models. Experimental results demonstrate that ACP-CapsPred exhibits satisfactory predictive capabilities in both stages, reaching state-of-the-art performance. In the first stage, ACP-CapsPred achieves accuracies of 80.25% and 95.71%, as well as F1-scores of 79.86% and 95.90%, on benchmark datasets Set 1 and Set 2, respectively. In the second stage, tasked with characterizing the functional activities of ACPs across five selected cancer types, ACP-CapsPred attains an average accuracy of 90.75% and an F1-score of 91.38%. Furthermore, ACP-CapsPred demonstrates excellent interpretability, revealing regions and residues associated with anticancer activity. Consequently, ACP-CapsPred presents a promising solution to expedite the development of ACPs and offers a novel perspective for other biological sequence analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.